| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
14,410,000 |
| Market
Cap: |
4.80(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.3333 - $0.3333 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Diagnostic Substances |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile ARCA biopharma is a clinical-stage biopharmaceutical company. Co.'s primary product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2 (AB201)) as a potential treatment for COVID-19, the disease syndrome caused by the SARS-CoV-2 virus, and potentially other viral diseases and Gencaro™ (bucindolol hydrochloride) for the treatment of atrial fibrillation in patients with chronic heart failure. rNAPc2 targets COVID-19 patients with biomarker evidence of coagulopathy, while Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-03-07 |
2023-12-05 |
2023-06-06 |
2022-06-06 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Titus Gary |
Chief Acct.Officer |
• – – |
2006-08-25 |
4 |
S |
$19.88 |
$797,502 |
D/D |
(40,000) |
2,633 |
|
- |
|
| Titus Gary |
Chief Acct.Officer |
• – – |
2006-08-25 |
4 |
OE |
$9.17 |
$372,100 |
D/D |
40,000 |
22,633 |
|
- |
|
| Titus Gary |
Chief Acct.Officer |
• – – |
2006-08-24 |
4 |
S |
$19.50 |
$292,500 |
D/D |
(15,000) |
2,633 |
|
- |
|
| Titus Gary |
Chief Acct.Officer |
• – – |
2006-08-24 |
4 |
OE |
$9.83 |
$147,375 |
D/D |
15,000 |
17,633 |
|
- |
|
| Sobel Burton E |
Director |
– • – |
2006-08-10 |
4 |
S |
$16.00 |
$200,000 |
D/D |
(12,500) |
0 |
|
- |
|
| Sobel Burton E |
Director |
– • – |
2006-08-10 |
4 |
OE |
$6.50 |
$81,250 |
D/D |
12,500 |
12,500 |
|
- |
|
| Titus Gary |
VP Finance, Chief Acct.Officer |
• – – |
2006-05-31 |
4 |
A |
$13.90 |
$1,251 |
D/D |
90 |
2,633 |
|
- |
|
| Love Ted W |
C.E.O. |
• • – |
2006-05-31 |
4 |
A |
$13.90 |
$15,735 |
D/D |
1,132 |
4,423 |
|
- |
|
| Levy Michael D |
Sr. VP Research & Development |
• – – |
2006-05-31 |
4 |
A |
$13.90 |
$9,744 |
D/D |
701 |
3,687 |
|
- |
|
| Bendekgey E Lee |
Sr VP & General Counsel |
• – – |
2006-05-31 |
4 |
A |
$13.90 |
$2,627 |
D/D |
189 |
898 |
|
- |
|
| Sobel Burton E |
Director |
– • – |
2006-05-26 |
4/A |
S |
$15.59 |
$134,048 |
D/D |
(8,600) |
0 |
|
- |
|
| Sobel Burton E |
Director |
– • – |
2006-05-26 |
4 |
S |
$15.59 |
$134,048 |
D/D |
(8,600) |
52,500 |
|
- |
|
| Sobel Burton E |
Director |
– • – |
2006-05-25 |
4/A |
OE |
$6.73 |
$98,788 |
D/D |
12,500 |
1,100 |
|
- |
|
| Sobel Burton E |
Director |
– • – |
2006-05-25 |
4/A |
S |
$15.58 |
$60,770 |
D/D |
(3,900) |
0 |
|
- |
|
| Sobel Burton E |
Director |
– • – |
2006-05-25 |
4 |
S |
$15.58 |
$60,770 |
D/D |
(3,900) |
61,100 |
|
- |
|
| Gavin James R III |
Director |
– • – |
2006-05-24 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
25,000 |
|
- |
|
| Titus Gary |
VP Finance, Chief Acct.Officer |
• – – |
2006-02-28 |
4 |
A |
$7.38 |
$1,247 |
D/D |
169 |
1,543 |
|
- |
|
| Bendekgey E Lee |
Sr VP & General Counsel |
• – – |
2006-02-28 |
4 |
A |
$7.38 |
$2,620 |
D/D |
355 |
709 |
|
- |
|
| Titus Gary |
VP Finance, Chief Acct.Officer |
• – – |
2005-11-30 |
4 |
A |
$7.40 |
$1,251 |
D/D |
169 |
1,374 |
|
- |
|
| Bendekgey E Lee |
Sr VP & General Counsel |
• – – |
2005-11-30 |
4 |
A |
$7.40 |
$2,620 |
D/D |
354 |
354 |
|
- |
|
| Titus Gary |
VP Finance, Chief Acct.Officer |
• – – |
2005-08-31 |
4 |
A |
$6.33 |
$1,114 |
D/D |
176 |
1,205 |
|
- |
|
| Love Ted W |
C.E.O. |
• • – |
2005-08-31 |
4 |
A |
$6.33 |
$5,779 |
D/D |
913 |
3,291 |
|
- |
|
| Levy Michael D |
Sr. VP Research & Development |
• – – |
2005-08-31 |
4 |
A |
$6.33 |
$9,495 |
D/D |
1,500 |
2,986 |
|
- |
|
| Levy Michael D |
Sr. VP Research & Development |
• – – |
2005-05-31 |
4 |
A |
$6.30 |
$9,362 |
D/D |
1,486 |
1,486 |
|
- |
|
| Titus Gary |
VP Finance, Chief Acct.Officer |
• – – |
2005-05-31 |
4 |
A |
$6.30 |
$1,052 |
D/D |
167 |
167 |
|
- |
|
240 Records found
|
|
Page 9 of 10 |
|
|
